English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The treatment schedule was shown in Figure 1 and To the editor: Neovascular glaucoma (NVG) is refractory glaucoma characterized by neovascularization of iris or explained in brief as follow. IOP was lowered as soon as anterior chamber angle, which often leads to dramatic elevation of intraocular pressure (IOP) and severe vision loss. Series of studies have been reported regarding managing NVG with anti-vascular endothelial growth factor (VEGF) therapy or in combination with antiglaucoma surgery. However, the effect of anti-VEGF seems only temporary and it does not improve the prognosis in the long term. Therefore, pan retinal photocoagulation (PRP) remains necessary for improving long term prognosis. However, it is not easy to complete PRP early in NVG patients due to corneal edema, hyphema, or vitreous hemorrhage. We conducted this prospective interventional case series study to propose a protocol which could confine NVG in an early stage. The aims of our treatment modalities included that controlling IOP immediately, complete PRP as soon as possible, antiVEGF as adjuvant and controlling residual glaucoma with gradual cyclophotocoagulation.

chinese medical journal/chinese medical journal

Early vitrectomy combined with pan retinal photocoagulation, anti-vascular endothelial growth factor, and gradual cyclophotocoagulation for treatment of neovascular glaucoma